Two of Opus's seven gene therapy assets are in clinical trials, with additional programs expected to enter the clinic.

We built TheraTrack to make therapy feel even clearer and more supportive. With simple visual tools, clients and clinicians can stay aligned and make informed decisions together throughout care.” — ...

Ocugen has announced the publication of positive results from its phase 1 GARDian1 trial of OCU410ST, a gene therapy for ...

Acanthamoeba keratitis (AK) is a rare but devastating eye infection caused by a free-living amoeba found in water and soil.

Researchers have explored potential treatment that could bring unexpected relief to people living with severe vision loss.The ...

Introduction Visual Hallucinations (VHs) (seeing things that others do not, or visions) are a common feature of psychosis, causing significant distress and disability. Services rarely ask about these ...

Cell and gene therapies use the body's building blocks - cells and genetic material - to boost the immune system or correct ...

Red light therapy is an emerging treatment for certain types of hair loss. Dermatologists explain how it works, when to use ...

The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...

The FDA granted breakthrough therapy designation to privosegtor, a novel peptoid small molecule for the treatment of optic ...

The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...

Ocugen (OCGN) rated Buy as OCU410ST Stargardt trial advances; FDA/EMA alignment speeds path to approval. Read here for more ...